Left Main Coronary Artery Disease

Intravascular imaging-guided PCI showed benefit vs. angiography for patients with left main CAD, with significantly lower risk for cardiac death or spontaneous target vessel-related MI, researchers reported.

Increasing left main coronary artery plaque burden was associated with long-term all-cause and cardiac mortality in patients who did not have revascularization, even if the lumen area was preserved, researchers reported.

BOSTON — In the all-comers SCAAR registry of patients with left main CAD who underwent revascularization in Sweden, PCI was associated with higher mortality rates compared with CABG.

Among patients with left main CAD, the incidence of MACCE was similar with coronary revascularization in male and female patients, according to 10-year results of the PRECOMBAT trial.

Long-term outcomes of PCI with a sirolimus-eluting stent vs. CABG for unprotected left main CAD.

Ten-year extended follow-up of the PRECOMBAT trial demonstrates no difference in the incidence of major adverse cardiac or cerebrovascular events regardless of whether patients with unprotected left main CAD were treated with PCI with a first-generation drug-eluting stent or CABG.

Editor’s Note: The following is a response written by the EXCEL trial leadership to claims of improper conduct of the trial, as outlined in a Healio article posted on Dec. 12, 2019. The EXCEL trial leadership response was issued on Dec. 12. Healio is posting the response in its entirety at the request of the authors.

The European Association for Cardio-Thoracic Surgery has withdrawn its support for the left main disease recommendations of the 2018 European Association for Cardio-Thoracic Surgery/European Society of Cardiology Clinical Guidelines for Myocardial Revascularization, but a portion of the association’s explanation has drawn criticism from the Society for Cardiovascular Angiography and Interventions.